Home Healthcare IT Global Ovarian Cancer Market Size, Top Share, Growth and Report to 2032

Ovarian Cancer Market

Ovarian Cancer Market Size, Share & Trends Analysis Report By Type (Epithelial Tumors, Germ Cell Tumors, Stromal Tumors, Primary Peritoneal Cancer), By Diagnosis (Computed Tomography (C.T.) Scans, Ultrasound, Barium Enema X-Ray, Magnetic Resonance Imaging (MRI) Scans, Chest X-Ray, Positron Emission Tomography (PET) Scan, Other Diagnostic Tests), By Therapeutic Treatment (Chemotherapy, Radiation Therapy, Targeted Therapy, Hormone Therapy, Other Therapeutic Treatments, Surgery), By Route of Administration (Oral, Parenteral, Others), By Drugs (Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics, Others), By End-User (Hospitals, Diagnostic Centers, Drug Stores, Online Pharmacies, Other End Users) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI31DR
Study Period 2020-2032 CAGR 23.8%
Historical Period 2020-2022 Forecast Period 2024-2032
Base Year 2023 Base Year Market Size USD 2.72 billion
Forecast Year 2032 Forecast Year Market Size USD 21.92 billion
Largest Market North America Fastest Growing Market Europe
The sample report only takes 30 secs to download, no need to wait longer.

Market Overview

The global ovarian cancer market size was worth USD 2.72 billion in 2023 and is expected to grow at a 23.8% CAGR between 2023 and 2032 and reach around USD 21.92 billion. 

Ovarian cancer affects the ovaries, part of a woman's reproductive system. In cancerous and low malignant potential cases, ovarian cancer begins at the distal end of the fallopian tubes. It tends to spread to the ovaries and the rest of the body. The lining of the ovaries is made up of three types of cells that can develop into various tumors, both benign and malignant. Blood tests, pelvic examinations, ultrasounds, and other diagnostic tests such as PET scans, magnetic resonance imaging (MRI), and C.T. scans are all available to detect ovarian cancers. The International Federation of Gynecology and Obstetrics (FIGO) and the American Joint Committee on Cancer (AJCC) are two staging systems for ovarian cancer (AJCC).

The market is being driven by a rise in the frequency of ovarian cancer, a growing geriatric population, and unhealthy lifestyles. According to the American Cancer Society, ovarian cancer is the fifth leading cause of cancer death in women in the United States, with more deaths than any other cancer of the reproductive system. According to the American Cancer Society, more than 19,880 women in the United States are expected to be diagnosed with ovarian cancer in 2021. Other factors expected to drive market growth during the forecast period 2022–2030 include an increase in the adoption of novel drugs and ongoing research and development for ovarian cancer treatment and diagnostic options.

Rising healthcare expenditures and favorable government policies stimulate the market's growth. However, apart from this, the market is expected to benefit from the robust development pipelines of major global players. The market is expected to grow due to improved chemotherapy drugs and advancements in radiation therapy.

The launch of generic drugs such as Gemzar, Taxol, Hycamtin, and Paraplatin and a lack of skilled professionals for cancer diagnosis are the major factors restricting the market growth. Another factor impacting market expansion is a lack of awareness about ovarian cancer among women in developing countries.

Market Dynamics

Global Market Drivers

The Increased Prevalence of Ovarian Cancer and the Number of Elderly Women

The expansion of healthcare is being driven by the growing economies of both developed and developing countries. As a result, they are helping to move the global market forward. The global market is expected to grow due to the ageing female population, rising incidence of ovarian cancer, the ease of using new treatments and therapies, and increasing healthcare spending. As the female population has gotten older, ovarian cancer has become more common. Rising ovarian cancer prevalence, the introduction of new medications and therapies, increased healthcare expenditure, and increased government funding drive the market forward.

The Ovarian Cancer Market is Being Propelled by Rising Healthcare Awareness

As a result, drugs such as Bevacizumab (Avastin) and Pazopanib (Votrient) are expected to boost the market, which is currently dominated by generics such as paclitaxel and carboplatin. The development of new medications to treat this type of cancer is expected to benefit the market significantly.

The global ovarian cancer treatment market is supported by ongoing research and development to develop effective treatment interventions for various disorders. Several ovarian cancer treatments are currently undergoing clinical trials and are expected to hit the market soon.

The Patent Expiration of Some of the Industries Encourages New Companies

The patent expiration of some of the industry's most well-known pharmaceuticals may help propel the industry forward by encouraging new companies to enter the market. During the forecast period, these shifting dynamics are expected to drive the market. The increasing adoption rate of new combination therapies for treatment is a significant factor driving this market's growth. The global market is being boosted by increased funding for research and the development of effective treatment techniques and advanced therapeutics for treating ovarian cancer.

Regional Analysis

The global ovarian cancer market share is divided into four regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

North America Dominates the Global Ovarian Cancer Market

North America dominates the global market owing to the constantly rising and huge geriatric population pool and advanced diagnostic centres available in the region. The demographic shift in North America is expected to accelerate market growth. According to the Population Reference Bureau, the number of Americans aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. The 65-and-older age group's share of the total population will rise from 16 % to 23 %. Another factor driving market growth in the region is the high prevalence and death rate of ovarian cancer. According to the National Cancer Institute, the incidence rate of ovarian cancer is 11.6 per 100,000 women in the United States, with a death rate of 7.2 per 100,000 women. In 2019, more than 233,565 women in the United States were diagnosed with ovarian cancer.

The European market is expected to account for most of the global market. The high prevalence of ovarian cancer in the region is the primary driver of the market. According to Cancer Research U.K., 7,495 new cases of ovarian cancer were diagnosed in the United Kingdom each year between 2016 and 2018. Aside from that, the incidence rate of ovarian cancer in the United Kingdom is expected to rise by 15% between 2015 and 2035, reaching 32 cases per 100,000 women. Other factors supporting market growth in Europe include ongoing research and development of drugs for the treatment of ovarian cancer and the presence of significant players in the region.

Due to the constantly growing geriatric population and advancements in ovarian cancer treatment and diagnostics, Asia Pacific is expected to grow at the fastest CAGR.

Because of poor healthcare infrastructure and low per capita income, Latin America, the Middle East, and Africa are expected to have the smallest global ovarian cancer market share.

Report Scope

Report Metric Details
Segmentations
By Type
  1. Epithelial Tumors
  2. Germ Cell Tumors
  3. Stromal Tumors
  4. Primary Peritoneal Cancer
By Diagnosis
  1. Computed Tomography (C.T.) Scans
  2. Ultrasound
  3. Barium Enema X-Ray
  4. Magnetic Resonance Imaging (MRI) Scans
  5. Chest X-Ray
  6. Positron Emission Tomography (PET) Scan
  7. Other Diagnostic Tests
By Therapeutic Treatment
  1. Chemotherapy
  2. Radiation Therapy
  3. Targeted Therapy
  4. Hormone Therapy
  5. Other Therapeutic Treatments
  6. Surgery
By Route of Administration
  1. Oral
  2. Parenteral
  3. Others
By Drugs
  1. Mitotic Inhibitors
  2. Antirheumatics
  3. Antipsoriatics
  4. VEGF/VEGFR inhibitors
  5. PARP inhibitors
  6. Antineoplastics
  7. Others
By End-User
  1. Hospitals
  2. Diagnostic Centers
  3. Drug Stores
  4. Online Pharmacies
  5. Other End Users
Company Profiles Bristol-Myers Squibb AstraZeneca Genentech Inc. Eli Lilly and Company Novogen, Inc. Roche Ltd. GlaxoSmithKline plc Boehringer Ingelheim GmbH Janssen Pharmaceuticals, Inc. Tesaro Inc. Aetera Zenteris Inc. Clovis Oncology Pfizer AbbVie ImmunoGen Johnson & Johnson Oasmia Pharmaceuticals
Geographies Covered
North America U.S. Canada
Europe U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
APAC China Korea Japan India Australia Taiwan South East Asia Rest of Asia-Pacific
Middle East and Africa UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
LATAM Brazil Mexico Argentina Chile Colombia Rest of LATAM
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Segmental Analysis

The symptoms of ovarian cancer are frequently ignored and easily confused with those of other illnesses, resulting in a lack of early detection and accurate diagnosis. The market for ovarian cancer diagnostics and treatments in Asia-Pacific is hampered. Other organs affected by ovarian cancer include the abdominal cavity, pelvis, abdominal lymph nodes, bones, liver, brain, and lymph node sac. Furthermore, the global market is being stifled by the expiration of crucial pharmaceutical patents. The market may face a problem as it develops increasingly effective drugs.

The lack of adequate technology for the early detection of ovarian cancer is a major challenge impeding the market. Furthermore, the shortage of skilled professionals poses a challenge to the market's growth. In addition, the ovarian cancer market's growth is being hampered by a lack of funding for research and development.

The global ovarian cancer market share is segmented into type, treatment, end-user, and region.

The market is classified into three types: epithelial tumours, germ cell tumours, and stromal tumours. The epithelial tumour segment is anticipated to lead the global market in type. The high prevalence of epithelial tumours is the primary factor driving the segmental market from 2022 to 2030. The segment of germ cell tumours is projected to expand, followed by the segment of stromal tumours.

The market is segregated into diagnosis, treatment, and surgery based on treatment. The market is divided into three categories based on treatment: diagnosis, treatment, and surgery. C.T. scans, Ultrasound, Barium enema x-ray, Magnetic resonance imaging (MRI) scans, Chest x-ray, Positron emission tomography (PET) scans, and other diagnostic tests are all used to diagnose. Chemotherapy, radiation therapy, targeted therapy, hormone therapy, and other treatments are all sub-categories of treatment. Because of the wide range of treatment options available, treatment is expected to account for a large portion of the global market. Due to advancements in the diagnostics sector worldwide, the diagnosis segment is expected to grow rapidly.

The market is divided into hospitals, diagnostic centres, drug stores, online pharmacies, and others based on end-users. Due to the availability of advanced facilities for the treatment of ovarian cancer, hospitals are expected to contribute the largest share of the market among end-users, followed by diagnostic centres. Because of the global launch of new and advanced drugs for the treatment of ovarian cancer, online pharmacies and drug stores are predicted to gain at a steady rate.

Market Size By Type

Market Size By Type
  • Epithelial Tumors
  • Germ Cell Tumors
  • Stromal Tumors
  • Primary Peritoneal Cancer
  • Recent Developments

    May 2022: Roche has partnered with the Global Fund to support low- and middle-income countries in strengthening critical diagnostics infrastructure.

    09 September 2021: Boehringer Ingelheim Acquired Abexxa Biologics to Further Expand its Research Efforts in Cancer Immunology and Novel Immunotherapeutic Approaches.

    Key Players

    Ovarian Cancer Market Share of Key Players

    Ovarian Cancer Market Share of Key Players
    Bristol-Myers Squibb AstraZeneca Genentech Inc. Eli Lilly and Company Novogen, Inc. Roche Ltd. GlaxoSmithKline plc Boehringer Ingelheim GmbH Janssen Pharmaceuticals, Inc. Tesaro Inc. Aetera Zenteris Inc. Clovis Oncology Pfizer AbbVie ImmunoGen Johnson & Johnson Oasmia Pharmaceuticals Others

    Frequently Asked Questions (FAQs)

    What is the estimated growth rate (CAGR) of the global ovarian cancer market?
    The global ovarian cancer market size is growing at a CAGR of 23.8% from 2024 to 2032.
    North America has the largest share of the market.
    The increased prevalence of ovarian cancer and the number of elderly women are the key driver for the growth of the market.
    The key players in the global market include Bristol-Myers Squibb, AstraZeneca, Genentech Inc, Eli Lilly and Company, Novogen, Inc, Roche Ltd, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc, Tesaro Inc, Aetera Zenteris Inc, Clovis Oncology, Pfizer, AbbVie, ImmunoGen, Johnson & Johnson, Oasmia Pharmaceuticals


    We are featured on :